A possible new mechanism in the pathophysiology of polycystic ovary syndrome (PCOS): The discovery that leukocyte telomere length is strongly associated with PCOS

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages

  Li, Qiaoli ^a,b   Du, Jing ^d   Feng, Ruizhi ^a,b   Xu, Yao ^a,b   Wang, Haojue ^a,b   Sang, Qing ^a,b   Xing, Qinghe ^b   Zhao, Xinzhi ^b   Jin, Li ^a   He, Lin ^b,c   Wang, Lei ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGING; FEMALE; HUMANS; LEUKOCYTES; POLYCYSTIC OVARY SYNDROME; TELOMERE; TELOMERE SHORTENING;

EID: 84893807108     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3685     Document Type: Article

References (47)

1. Ehrmann DA. Polycystic ovary syndrome.NEngl J Med. 2005;352: 1223-1236.
2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18:774-800.
3. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91:2100-2104.
4. Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update. 2005;11:631-643.
5. Zhao H, Chen ZJ. Genetic association studies in female reproduction: from candidate-gene approaches to genome-wide mapping. Mol Hum Reprod. 2013;19:644-654.
6. Shi Y,ZhaoH, Shi Y, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012; 44:1020-1025.
7. Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011;43:55-59.
8. Armanios M. Telomeres and age-related disease: how telomere biology informs clinical paradigms. J Clin Invest. 2013;123:996-1002.
9. Blackburn EH. Switching and signaling at the telomere. Cell. 2001; 106:661-673.
10. Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet. 2012;13:693-704.
11. Nordfjäll K, Larefalk A, Lindgren P, Holmberg D, Roos G. Telomere length and heredity: Indications of paternal inheritance. Proc Natl Acad Sci U S A. 2005;102:16374-16378.
12. Mathon NF, Lloyd AC. Cell senescence and cancer. Nat Rev Cancer. 2001;1:203-213.
13. Roger L, Jones RE, Heppel NH, Williams GT, Sampson JR, Baird DM. Extensive telomere erosion in the initiation of colorectal adenomas and its association with chromosomal instability. J Natl Cancer Inst. 2013;105:1202-1211.
14. Svenson U, Nordfjäll K, Stegmayr B, et al. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res. 2008;68:3618-3623.
15. Brouilette SW, Moore JS,McMahonAD, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet. 2007;369:107-114.
16. Shen Q, Zhao X, Yu L, et al. Association of leukocyte telomere length with type 2 diabetes in mainland Chinese populations. J Clin Endocrinol Metab. 2012;97:1371-1374.
17. Cohen S, Janicki-Deverts D, Turner RB, et al. Association between telomere length and experimentally induced upper respiratory viral infection in healthy adults. JAMA. 2013;309:699-705.
18. MurriM,Luque-RamírezM,InsenserM,Ojeda-OjedaM,Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013;19:268-288.
19. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237-4245.
20. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30:e47.
21. Fyhrquist F, Saijonmaa O, Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol. 2013;10:274-283.
22. Codd V, Nelson CP, Albrecht E, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet. 2013;45:422-427, 427e1-e2.
23. Bekaert S, De Meyer T, Rietzschel ER, et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell. 2007;6:639-647.
24. Campisi J. Cellular senescence: putting the paradoxes in perspective. Curr Opin Genet Dev. 2011;21:107-112.
25. Vulliamy T, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 2001;413:432-435.
26. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007; 356:1317-1326.
27. Yamaguchi H, Baerlocher GM, Lansdorp PM, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood. 2003;102:916-918.
28. Haque S, Rakieh C, Marriage F, et al. Shortened telomere length in patients with systemic lupus erythematosus. Arthritis Rheum. 2013; 65:1319-1323.
29. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008;8:450-458.
30. Kao HT, Cawthon RM, Delisi LE, et al. Rapid telomere erosion in schizophrenia. Mol Psychiatry. 2008;13:118-119.
31. Yang Z, Ye J, Li C, et al. Drug addiction is associated with leukocyte telomere length. Sci Rep. 2013;3:1542.
32. Cheng EH, Chen SU, Lee TH, et al. Evaluation of telomere length in cumulus cells as a potential biomarker of oocyte and embryo quality. Hum Reprod. 2013;28:929-936.
33. Eagleson CA, Gingrich MB, Pastor CL, et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin- releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. 2000;85:4047-4052.
34. Mai K, Bobbert T, Reinecke F, et al. Intravenous lipid and heparin infusion-induced elevation in free fatty acids and triglycerides modifies circulating androgen levels in women: a randomized, controlled trial. J Clin Endocrinol Metab. 2008;93:3900-3906.
35. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update. 2005; 11:357-374.
36. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7:219-231.
37. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44-84.
38. von Zglinicki T. Role of oxidative stress in telomere length regulation and replicative senescence. Ann NY Acad Sci. 2000;908:99-110.
39. Petersen S, Saretzki G, von Zglinicki T. Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp Cell Res. 1998;239:152-160.
40. Zhang H, Pan KH, Cohen SN. Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proc Natl Acad SciUSA. 2003;100:3251-3256.
41. Sahin E, Colla S, Liesa M, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature. 2011;470:359-365.
42. Guo N, Parry EM, Li LS, et al. Short telomeres compromise β-cell signaling and survival. PLoS One. 2011;6:e17858.
43. Zhao J, Zhu Y, Lin J, et al. Short leukocyte telomere length predicts risk of diabetes in American Indians: the Strong Heart Family Study [published online August 15, 2013]. Diabetes. doi:10.2337/db13- 0744.
44. Carmina E. Ovarian and adrenal hyperandrogenism. Ann NY Acad Sci. 2006;1092:130-137.
45. Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5α-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab. 2003;88:5907-5913.
46. Moghetti P, Castello R, Negri C, et al. Insulin infusion amplifies 17 α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab. 1996;81:881-886.
47. Carmina E, Gonzalez F, Vidali A, Stanczyk FZ, Ferin M, Lobo RA. The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome. Hum Reprod. 1999;14:307-311.